Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017)

Coherus Oncology (CHRS) has 5 years of Current Deferred Revenue data on file, last reported at $669000.0 in Q1 2017.

• For the quarter ending Q1 2017, Current Deferred Revenue fell 98.65% year-over-year to $669000.0; the trailing twelve-month figure through Mar 2017 stood at $669000.0 (down 98.65% YoY), and the FY2016 full-year result was $892000.0, down 98.2% from the prior year.
• Current Deferred Revenue retreated to $669000.0 in Q1 2017, from $892000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $61.3 million in Q2 2016 to a low of $162000.0 in Q1 2015.
• A 5-year average of $22.0 million and a median of $22.8 million in 2014 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 30537.65% in 2016 and slumped 98.65% in 2017, its largest moves.
• Tracing CHRS's Current Deferred Revenue over 5 years: stood at $14.3 million in 2013, then soared by 59.63% to $22.8 million in 2014, then surged by 117.64% to $49.6 million in 2015, then plunged by 98.2% to $892000.0 in 2016, then dropped by 25.0% to $669000.0 in 2017.
• Business Quant data shows CHRS's Current Deferred Revenue at $669000.0 in Q1 2017, $892000.0 in Q4 2016, and $1.4 million in Q3 2016.